Coya Therapeutics
COYACOYA · Stock Price
Historical price data
Overview
Coya Therapeutics' mission is to develop novel Treg-enhancing therapies to address chronic inflammatory diseases driven by immune dysfunction. The company has achieved key milestones, including Health Canada CTA acceptance for a Phase 2 ALS trial and U.S. FDA IND clearance for Frontotemporal Dementia for its lead candidate COYA 302. Its strategy leverages a diversified platform of biologics, exosomes, and cell therapies to target multiple indications and patient populations. Recent private financing provides capital to advance its clinical programs.
Technology Platform
A multi-modality platform harnessing regulatory T cells (Tregs) through three approaches: Treg-enhancing combination biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.
Pipeline
1| Drug | Indication | Stage | Watch |
|---|---|---|---|
| COYA 302 + Placebo | Amyotrophic Lateral Sclerosis (ALS) | Phase 2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Coya competes with ALS-specific drug developers and a growing field of neuro-inflammation companies. Its primary differentiation is a Treg-focused, multi-modality platform, with its combination biologic approach offering a potentially faster development path versus complex cell therapies pursued by competitors like Sangamo and Sonoma Biotherapeutics.